The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.
April 24th 2024
Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
A Managed Care Focus on Assessing the Armamentarium for Multiple Sclerosis to Better Individualize Treatment
1.5 Credits / Neurology
View More
The Promising Role of Novel and Emerging Therapies for Amyotrophic Lateral Sclerosis: Clinical and Managed Care Insights
1.0 Credit / Neurology
View More
Strategies for the Management and Treatment of ALS: The Value of Early Diagnosis and Clinical Intervention
3.0 Credits / Neurology
View More
Leveraging Managed Care to Optimize Best Practices in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1.0 Credit / Neurology
View More
Improving Outcomes and Quality of Care in Spinal Muscular Atrophy: Updates in Treatment Advances
2.0 Credits / Neurology
View More
New and Emerging Treatment Strategies for Myasthenia Gravis: The Role of the Specialty Pharmacist
1.0 Credit / Neurology
View More
Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Caregiver Burden
1.5 Credits / Neurology
View More
Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care
1.5 Credits / Neurology
View More
High Efficacy Therapies in MS: Ocrelizumab, Ofatumumab, and Cladribine
Thomas Leist, MD and Darin Okuda, MD discuss clinical trials supporting the use of high efficacy MS therapies: ocrelizumab, ofatumumab, and cladribine.
Watch
Greater DMT Adherence Linked With Superior Outcomes Among Veterans With MS
July 14th 2021Results of a retrospective observational study indicate good adherence to disease-modifying therapies (DMTs) for multiple sclerosis (MS) is associated with better outcomes among veterans with the disease.
Read More
Risks of Undertreatment in MS and Impact of Early High Efficacy Therapy
Darin Okuda, MD discusses the risk of undertreating MS patients and the avoidance of undertreatment with newer high-efficacy therapies.
Watch
Study Offers New Tools to Differentiate Between MS, Neuromyelitis Optica Spectrum Disorder
June 25th 2021Although existing research has shown structural differences between multiple sclerosis (MS) and neuromyelitis optica spectrum disorder in following optic neuritis, the new report also covers non–optic neuritis eyes.
Read More
Early Intensive DMT Use May Prevent Greater Long-term Disability in RRMS
June 22nd 2021Early intensive treatment was more efficacious at slowing disease accumulation in patients with relapsing-remitting multiple sclerosis (RRMS) vs initiating therapy with a moderate-efficacy disease-modifying treatment (DMT) prior to switching to a higher-efficacy DMT.
Read More
Overview of Multiple Sclerosis
A multidisciplinary panel of experts provide an overview of the progressive nature of multiple sclerosis (MS) and discuss how clinicians, payers, and pharmacists approach management of the disease.
Watch
Adults With MS, Comorbidities Shoulder Significant Economic, Health Burdens
June 11th 2021The study authors hope their findings inform future interventions whose goal is to minimize the comorbidity burden of adults with multiple sclerosis (MS), thereby improving their quality of life and ultimate health outcomes.
Read More
Lower Risk of Relapse Seen Among UK Children With RRMS Receiving Newer DMTs
June 9th 2021Compared with their peers receiving injectable treatments for their relapsing-remitting multiple sclerosis (RRMS), children who received newer disease-modifying therapies (DMTs) had improved scores on several measures of disease progression.
Read More